CHOSA Oncology
CHOSA Oncology AB initiates payment of last portion of loan given to RhoVac AB
CEO Peter Buhl commenting: "After several administrative steps CHOSA has initiated the pay back process to fulfill our obligations towards the loan givers. I want to thank you all for your patience and for your support in developing products for hard-to-treat cancers."
This disclosure contains information that Chosa Oncology AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 08-04-2023 10:31 CET.
Datum | 2023-04-08, kl 10:31 |
Källa | Cision |
